IGEM is a Immuno-Oncology company (spun out of Kings College London) is focused on the development of IgE antibody drugs to fight cancer.
IGEM Therapeutics Ltd
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/igem-therapeutics-limited” connections=”true” suffix=””]
IGEM is building a portfolio of IgE antibodies directed against various cancer antigens including folate receptor alpha, CSPG4, HER2 and EGFR. The epsilon constant region of IgE has evolved to fight complex, multicellular parasitic organisms resident in tissue by recruiting powerful immune effector cells such as macrophages, basophils and monocytes. IGEM believes that potent immune responses arising from IgE are suited to the destruction of solid tumours which also reside in tissue. IGEM is also developing a novel antibody platform technology based on protein and glyco-engineering of the epsilon constant region.
In Apr 2018, IGEM Therapeutics collaborate with IONTAS Ltd . It will add to IGEMs pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study. IONTAS will utilise its proprietary antibody discovery technology to help IGEM identify novel IgE antibodies against two targets.
In May 2018, IGEM Therapeutics recieved £ 1.45 Mn funding grant from Innovate UK – UKs innovation agency. IGEM to use this Biomedical Catalyst fund for the further clinical development of IGEM-Ch, a novel IgE CSPG4 targeting antibody.
In June 2017, IGEM Therapeutics, announced the funding worth £2 Mn in Series A round from Epidarex Capital, a specialist early stage life science venture capital firm.